Scaling up antiretroviral therapy in resource-limited settings: Adapting guidance to meet the challenges

Current Opinion in HIV and AIDS

Volumn 8, Issue 1, 2013, Pages 12-18

  Vitoria, Marco ^a   Vella, Stefano ^b   Ford, Nathan ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

antiretroviral therapy; public health approach; scale up treatment guidelines

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GENERIC DRUG; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ATTITUDE TO ILLNESS; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LONG TERM CARE; MALNUTRITION; MORTALITY; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; REVIEW; SCALE UP; SURVIVAL; TREATMENT FAILURE; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; PUBLIC HEALTH;

EID: 84871921104     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835b8123     Document Type: Review

References (42)

1. Anon. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Geneva: WHO; 2002.
2. Galvao J. Access to antiretroviral drugs in Brazil. Lancet 2002; 360:1862-1865. (Pubitemid 35449428)
3. Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Global Health 2011; 7:33.
4. Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997; 350:245-250. (Pubitemid 27312294)
5. Hogg R, Cahn P, Katabira ET, et al. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002; 360:1710-1711. (Pubitemid 35447895)
6. Treating 3 million by 2005: making it happen. The WHO Strategy. Geneva: World Health Organization/UNAIDS; 2003.
7. Schwartlander B, Grubb I, Perriens J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541-546. (Pubitemid 44177530)
8. Anon. Scaling up antiretroviral therapy in resource-limited settings. Treatment guidelines for a public health approach. Geneva: WHO; 2003.
9. Progress on global access to HIV antiretroviral therapy. A report on '3 by 5' and beyond. Geneva: World Health Organization/UNAIDS; 2006.
10. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690. (Pubitemid 44200639)
11. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
12. Anon. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2006.
13. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34. (Pubitemid 38968622)
14. Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy for HIV be started? BMJ 2007; 334:76-78. (Pubitemid 46122238)
15. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8:679-688. (Pubitemid 46547020)
16. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567. (Pubitemid 41196755)
17. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002; 4:27-35. (Pubitemid 34464232)
18. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
19. Anon. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva: WHO; 2006.
20. Mills EJ, Ford N, Nabiryo C, et al. Ensuring sustainable antiretroviral provision during economic crises. AIDS 2010; 24:341-343.
21. Bygrave H, Ford N, van Cutsem G, et al. Implementing a tenofovir-based firstline regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr 2011; 56:e75-e78.
22. Anon. Antiretroviral therapy of HIV infection in infants and adolescents: recommendations for a public health approach. Geneva: WHO; 2010.
23. Mugglin C AK, Wools-Kaloustian K, Sterne J, et al., and IeDEA and ART-CC Collaborations. Immunodeficiency at the start of ART: global view. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 5-8 March 2012; Abstract 100.
24. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209-216.
25. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88. (Pubitemid 46340429)
26. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009; 103:601-606.
27. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
28. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a modelbased analysis. AIDS 2012; 26:1663-1672.
29. Undetectable: how viral load monitoring can improve HIV treatment in developing countries. Geneva: MSF; 2012.
30. WHO HIV drug resistance report. Geneva: World Health Organization; July 2012.
31. Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS 2012; 26:57-65.
32. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS 2007; 21 (Suppl 4):S89-S95. (Pubitemid 47051754)
33. MSF. Untangling the Web of antiretroviral price reductions. 15th ed. Geneva: MSF; 2012.
34. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
35. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
36. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009 systematic review. Trop Med Int Health 2010; 15 (Suppl 1):1-15.
37. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.
38. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to art care in sub-Saharan Africa: a systematic review. AIDS 2012; 26:2059-2067.
39. Barnighausen T, Salomon JA, Sangrujee N. HIV treatment as prevention: issues in economic evaluation. PLoS Med 2012; 9:e1001263.
40. Anon. Retention in HIV programs: defining the challenges and identifying solutions. Meeting Report; 13-15 September 2011. Geneva: World Health Organization; 2012.
41. The Strategic use of antiretrovirals for treatment and prevention of HIV infection. Report of a WHO technical consultation. Geneva: WHO; 14-16 November 2011. http://extranet.who.int/iris/restricted/bitstream/10665/70912/5/ 9789241503808-eng.pdf.
42. The strategic use of antiretrovirals for treatment and prevention of HIV infection: 2nd expert panel meeting. Geneva: WHO; 2-4 May 2012. http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.13-eng.pdf.